What is bacteriostatic water?
Bacteriostatic water is sterile water for injection with an antimicrobial preservative added, in practice benzyl alcohol at 0.9 percent. The preservative inhibits bacterial growth rather than killing bacteria, which is what allows the same container to be entered repeatedly. The United States Pharmacopeia defines it as a diluent, packaged in containers no larger than 30 mL.
Everything else follows from that one added ingredient. It sets the container size, the beyond-use convention, the neonatal warning on the label and the reason the preparation is treated as a multiple-dose article at all.
What the pharmacopoeia actually defines
Two compendial texts carry the definition. The USP monograph states that Bacteriostatic Water for Injection "is prepared from Water for Injection that is sterilized and suitably packaged, containing one or more suitable antimicrobial agents". USP General Chapter 1231, Water for Pharmaceutical Purposes, is more explicit about the purpose. It describes the preparation as "sterile Water for Injection to which has been added one or more suitable antimicrobial preservatives", states that it is intended as a diluent in the preparation of parenteral products, most typically for multi-dose products from which content is withdrawn repeatedly, and records that it may be packaged in single-dose or multiple-dose containers of no more than 30 mL.
The 30 mL ceiling is not a marketing decision. It is a compendial packaging limit, and it exists because a preserved container is expected to be entered many times over a limited period rather than emptied at once.
The compendial chain: the preservative is what the container limit, the multiple-dose format and the beyond-use convention all hang on.
| Property | Bacteriostatic Water for Injection, USP | Where it is stated |
|---|---|---|
| Base | Water for Injection, sterilised and suitably packaged | USP monograph |
| Added substance | one or more suitable antimicrobial preservatives | USP monograph, USP 1231 |
| Preservative in practice | benzyl alcohol, 0.9% (9 mg/mL) or 1.1% (11 mg/mL) | FDA label |
| Container | single-dose or multiple-dose, not larger than 30 mL | USP 1231 |
| pH | 5.7, range 4.5 to 7.0 | FDA label |
| Stated purpose | diluent for parenteral preparations, typically multi-dose articles requiring repeated withdrawals | USP 1231 |
| Stated indication | "only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered" | FDA label |
| Storage | 20 to 25 °C | FDA label |
| United States legal status | "Rx only" | FDA label |
Compendial and label values quoted for reference, not a dosing recommendation and not medical advice.
What "bacteriostatic" means
The word is doing precise work. A bacteriostatic agent inhibits the multiplication of bacteria; a bactericidal one reduces the population. In the antimicrobial literature the two are separated by the minimum inhibitory concentration, the lowest concentration that prevents visible growth, and the minimum bactericidal concentration, the lowest concentration that produces a roughly 99.99 percent reduction in the starting population. Pankey and Sabath, reviewing the distinction in Clinical Infectious Diseases in 2004, noted that the two categories are not pure: agents called bactericidal frequently fail to kill every organism within 18 to 24 hours, and most bacteriostatic agents kill a substantial share of the inoculum in the same window.
For a diluent the practical reading is narrow. A preserved liquid holds in check the small number of organisms that may be introduced when a closure is penetrated. It does not sterilise the closure, it does not rescue a container that has already been compromised, and it does not extend the sterility the sealed container left the factory with.
| Term | What it describes | What follows from it |
|---|---|---|
| Sterile | free of viable microorganisms at the point of manufacture and sealing | applies to the sealed container, not to what happens after entry |
| Bacteriostatic | inhibits the multiplication of bacteria | a small introduced population is held in check, not eliminated |
| Bactericidal | reduces a bacterial population, conventionally by 99.99 percent | describes an active reduction, which a preservative at preservative concentrations is not required to achieve |
| Preserved | contains an antimicrobial agent that has met antimicrobial effectiveness testing under USP General Chapter 51 | the precondition for the 28-day beyond-use date in USP General Chapter 797 |
Terminology and compendial conventions quoted for reference, not a dosing recommendation and not medical advice.
Benzyl alcohol, the one added ingredient
Benzyl alcohol is an aromatic alcohol, formula C7H8O, described by the European Medicines Agency as an excipient used for its preservative properties and as a solubilising agent. In the body it is metabolised to benzoic acid. Bis and colleagues describe it as the most widely used antimicrobial preservative in multi-dose protein formulations, which is why it turns up in the peptide and protein stability literature as often as it turns up on a water label.
The declared concentration converts straightforwardly into a total content per container, which is the figure the exposure literature works with.
| Labelled concentration | Per mL | In a 10 mL container | In a 30 mL container |
|---|---|---|---|
| 0.9% | 9 mg | 90 mg | 270 mg |
| 1.1% | 11 mg | 110 mg | 330 mg |
Unit arithmetic only, not a dosing recommendation and not medical advice.
What the FDA label says
The label for Bacteriostatic Water for Injection, USP published on DailyMed is short, and almost all of it is about the preservative rather than the water.
| Label element | Wording |
|---|---|
| Description | "sterile, nonpyrogenic preparation of water for injection containing 0.9% (9 mg/mL) or 1.1% (11 mg/mL) of benzyl alcohol" |
| Container | "supplied in a multiple-dose container from which repeated withdrawals may be made" |
| Indication | "indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer" |
| Neonates | "NOT FOR USE IN NEONATES"; benzyl alcohol "has been associated with toxicity in neonates" |
| Neonates, continued | the label states that "only preservative-free Sterile Water for Injection should be used" in this group |
| Neuraxial routes | "Parenteral preparations containing benzyl alcohol should not be used in epidural or spinal anesthesia procedures" |
| Administration without a solute | "Intravenous administration of Bacteriostatic Water for Injection without a solute may result in hemolysis" |
| Tonicity | not for intravenous use "unless the osmolar concentration of additives results in an approximate isotonic admixture" |
| Legal status | "Rx only" |
| Storage | "Store at 20 to 25°C (68 to 77°F)" |
Compendial and label values quoted for reference, not a dosing recommendation and not medical advice.
Two of those lines are easy to misread. The indication is not a general licence to dilute anything: it is expressly subordinated to the instructions of the manufacturer of the drug being dissolved. And the haemolysis warning is about the water itself, not the preservative. Water without a solute is hypotonic, and hypotonic fluid entering the bloodstream lyses red cells, which is why the tonicity of the finished admixture is a label concern in its own right.
Where the neonatal warning comes from
The warning is not boilerplate. In 1982 Gershanik and colleagues described in the New England Journal of Medicine ten premature infants who developed progressive neurological deterioration, severe metabolic acidosis, gasping respirations and cardiovascular collapse, traced to benzyl alcohol in flush solutions. In the same year the CDC recorded sixteen such deaths in the Morbidity and Mortality Weekly Report, together with the FDA recommendation that intravascular flush solutions containing benzyl alcohol not be used for newborns and that diluents with this preservative not be used as medications for these infants.
The European position is set out in the EMA questions-and-answers document on benzyl alcohol as an excipient, which the agency maintains as the assessment basis for benzyl alcohol content in applications for the authorisation of medicinal products. It records that intravenous administration in the range of 100 to 200 mg/kg/day has been linked to the gasping syndrome in pre-term newborns, that the underlying problem is accumulation caused by metabolic immaturity, and that the minimum amount at which toxicity may occur is not known. The EMA also notes that children under three may not metabolise it as efficiently as adults.
| Question | Position recorded by the EMA |
|---|---|
| Reported toxic range, intravenous | 100 to 200 mg/kg/day linked to the gasping syndrome in pre-term newborns |
| Threshold for a leaflet statement | zero, for all routes of administration |
| Newborns | not to be given to babies up to four weeks old other than on medical advice |
| Children under three years | the EMA records that metabolism may be less efficient than in adults and requires a corresponding leaflet statement |
| Liver or kidney impairment | the EMA records accumulation and a risk of metabolic acidosis as the reason benzyl alcohol content is assessed separately in these patients |
Regulatory reference values quoted from the EMA document, not a dosing recommendation and not medical advice.
These figures are assessment criteria applied by regulators to the excipient content of authorised medicinal products; they are not a permitted amount for any individual.
Shelf life in brief
An unopened container is governed by the expiry date printed on it, and the label's storage instruction is 20 to 25 °C. Once the closure has been entered, USP General Chapter 797 assigns a beyond-use date of 28 days to a preserved multiple-dose container unless the manufacturer specifies otherwise, and CDC injection-safety guidance repeats the same figure, adding that an entered vial should be dated. The 28 days are a convention about the container, not a stability claim about anything dissolved in it. The unopened-versus-entered distinction, the refrigeration question and what the 28 days do and do not cover are set out in how long bacteriostatic water lasts.
What the preservative changes
Bacteriostatic water and its unpreserved counterpart both start as water for injection; the preserved version has an antimicrobial agent added and the unpreserved one does not. That single difference is why one is packaged at up to 30 mL for repeated entry and the other at up to 1 L for a single entry, and why their beyond-use conventions are measured in weeks and hours respectively. The comparison with unpreserved sterile water and with saline is covered separately in bacteriostatic water vs sterile water.
pH, and the absence of a buffer
The FDA label gives a pH of 5.7 with a permitted range of 4.5 to 7.0, which is mildly acidic. More important than the number is what is missing: there is no buffer system. A buffered vehicle resists a shift in pH when something is dissolved in it; an unbuffered one does not. The pH of the finished solution is therefore set by the solute and its counterion rather than by the water, and combining several unbuffered solutions lets those pH values drift without resistance. That mechanism, and the precipitation that can follow it, is described in mixing peptides in one syringe.
Bacteriostatic water for peptides
"Bac water" is the common shorthand, and the reason it is associated with lyophilised peptide material is structural rather than chemical. A lyophilised powder in a multiple-dose container is designed around repeated withdrawals, and repeated withdrawal from one container is a recognised practice only where a preservative is present. USP General Chapter 1231 names exactly that use case, and USP General Chapter 797 attaches the 28-day beyond-use date to preserved containers alone. Which diluent belongs with a given preparation is determined by that preparation's own instructions; for a licensed medicine, the label and the leaflet decide, and no general rule about water overrides them.
The pharmaceutical literature also records that a preservative is not an inert bystander in a peptide or protein solution. Benzyl alcohol can interact with the molecule it preserves, and whether it does so at all, and in which direction, is specific to the molecule and the excipient studied.
| Reported observation | System studied | Reference |
|---|---|---|
| Benzyl alcohol induced aggregation in a concentration-dependent way, through partial rather than complete unfolding; the apparent aggregation temperature fell linearly as concentration rose | a recombinant interferon | Bis et al., Journal of Pharmaceutical Sciences, 2015 |
| Benzyl alcohol increased aggregation in reconstituted lyophilised formulations; structural perturbation during freeze-drying, protein concentration and storage temperature were identified as determinants | a recombinant receptor antagonist protein | Roy et al., Journal of Pharmaceutical Sciences, 2005 |
| Benzyl alcohol showed no detectable interaction with the peptide and did not induce aggregation; m-cresol at 1% (w/v) produced insoluble aggregates through site-specific interactions | one acylated 31-residue peptide (acyl-peptide A) | Li, Falk et al., Molecular Pharmaceutics, 2022 |
Published stability observations quoted for reference; they describe the formulations studied, not any other preparation, and are not a usage recommendation.
The pattern in that literature is that compatibility is established experimentally for one formulation at a time. Licensed multi-dose products carry that data because it was generated during development. Compounds that are not approved medicines do not, and the absence of formulation data is itself the relevant fact rather than a gap to be filled by analogy. Storage conditions for the reconstituted solution are a separate question again, covered in how to store peptides and peptide vials.
Where it appears in reconstitution arithmetic
The only quantitative role the water plays is as the volume term. The amount of solid in a container divided by the volume of diluent added gives the concentration in mg/mL, and that concentration is what any later conversion to syringe units depends on; the bacteriostatic water calculator performs that division, mg, mL and IU are not interchangeable units, and reading a U-100 syringe covers the volume markings themselves. The general procedure is described in reconstituting peptides.
Mathematical converter only, not a dosing recommendation and not medical advice.
Prescription status and what the label controls
The United States label carries the phrase "Rx only", a statement about classification under United States law and nothing more. A compendial designation and a legal classification are different objects: the USP name is a quality standard maintained by a pharmacopoeial body, while prescription, pharmacy-only or unclassified status is decided by each country's medicines legislation, and the first does not imply the second anywhere. Where a licensed medicine is being prepared, the controlling document remains that medicine's own label or summary of product characteristics.
Common questions
What is bacteriostatic water?
Bacteriostatic water is sterile water for injection to which one or more antimicrobial preservatives have been added, as defined in the United States Pharmacopeia. The preservative is normally benzyl alcohol at 0.9 percent (9 mg/mL). It is a compendial diluent rather than a medicine in its own right, and USP General Chapter 1231 states that it is packaged in containers no larger than 30 mL.
What does bacteriostatic mean?
Bacteriostatic means growth-inhibiting rather than killing. A bacteriostatic agent holds a bacterial population in check, while a bactericidal one reduces it, the two being distinguished in the literature by the minimum inhibitory concentration and the minimum bactericidal concentration. The categories overlap in practice, and a bacteriostatic liquid is in no sense a steriliser or a disinfectant.
What is Bacteriostatic Water for Injection, USP?
Bacteriostatic Water for Injection, USP is the compendial name of the preparation described in the United States Pharmacopeia and on the corresponding FDA label. That label describes a sterile, non-pyrogenic preparation of water for injection containing 0.9 percent (9 mg/mL) or 1.1 percent (11 mg/mL) benzyl alcohol, supplied in a multiple-dose container, and indicated only for diluting or dissolving drugs according to the instructions of the manufacturer of the drug concerned.
What is bacteriostatic water used for?
The FDA label states that the preparation is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to the instructions of the manufacturer of the drug to be administered. It is a pharmaceutical vehicle, not a treatment in its own right, and the label of the preparation being dissolved decides whether a preserved diluent is appropriate.
Why is bacteriostatic water the conventional diluent for multiple-dose vials?
Bacteriostatic water is the conventional diluent for multiple-dose containers because a preservative is what makes repeated entry into one container a recognised practice at all. USP General Chapter 1231 describes bacteriostatic water as intended for multi-dose products that require repeated content withdrawals, and USP General Chapter 797 ties the 28-day beyond-use date of an entered container to the presence of antimicrobial preservatives. An unpreserved container entered once is treated very differently. Whether a particular preparation is compatible with a preserved diluent is settled by that preparation's own instructions, not by the diluent.
Is bacteriostatic water prescription-only?
The United States label for Bacteriostatic Water for Injection, USP carries the statement Rx only. Outside the United States there is no single answer: the compendial name is a quality standard, while prescription status is set by each country's own medicines law. The USP designation therefore says nothing about how the preparation is classified in any other jurisdiction.
What is the pH of bacteriostatic water?
The FDA label states a pH of 5.7 with a permitted range of 4.5 to 7.0. The liquid is unbuffered, so it has almost no capacity to hold that value once something is dissolved in it, and the pH of the resulting solution is governed by the solute rather than by the water.
Sources
- USP-NF monograph, Bacteriostatic Water for Injection, United States Pharmacopeial Convention: https://doi.usp.org/USPNF/USPNF_M88830_03_01.html
- USP General Chapter 1231, Water for Pharmaceutical Purposes, USP-NF, United States Pharmacopeial Convention (definitions of Water for Injection, Sterile Water for Injection and Bacteriostatic Water for Injection, including the 30 mL container limit): https://doi.usp.org/USPNF/USPNF_M99956_07_01.html
- FDA label, Bacteriostatic Water for Injection, USP, via DailyMed (US National Library of Medicine): https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=42c6938e-f747-ae13-e063-6294a90a59a3
- FDA label, Bacteriostatic Water for Injection, USP, second listing on DailyMed (pH, storage, haemolysis warning): https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ccadcf46-6a6f-436b-9bbc-17e2983a335f
- USP General Chapter 797, Pharmaceutical Compounding, Sterile Preparations, Revision Bulletin: "The beyond-use date (BUD) for an opened or entered (e.g., needle-punctured) multiple-dose container with antimicrobial preservatives is 28 days (see Antimicrobial Effectiveness Testing 51), unless otherwise specified by the manufacturer." https://www.pbm.va.gov/linksotherresources/docs/usp797pharmaceuticalcompoundingsterilecompounding.pdf
- Centers for Disease Control and Prevention, Preventing Unsafe Injection Practices (dating and discarding multi-dose vials within 28 days): https://www.cdc.gov/injection-safety/hcp/clinical-safety/index.html
- European Medicines Agency, Questions and answers on benzyl alcohol used as an excipient in medicinal products for human use, EMA/CHMP/508188/2013: https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-benzyl-alcohol-used-excipient-medicinal-products-human-use_en.pdf
- Gershanik J, Boecler B, Ensley H, McCloskey S, George W. The gasping syndrome and benzyl alcohol poisoning. New England Journal of Medicine 1982;307(22):1384–1388: https://pubmed.ncbi.nlm.nih.gov/7133084/
- Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clinical Infectious Diseases 2004;38(6):864–870: https://pubmed.ncbi.nlm.nih.gov/14999632/
- Bis RL, Singh SM, Cabello-Villegas J, Mallela KMG. Role of benzyl alcohol in the unfolding and aggregation of interferon alpha-2a. Journal of Pharmaceutical Sciences 2015;104(2):407–415: https://pubmed.ncbi.nlm.nih.gov/25100180/
- Roy S, Jung R, Kerwin BA, Randolph TW, Carpenter JF. Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations. Journal of Pharmaceutical Sciences 2005;94(2):382–396: https://pubmed.ncbi.nlm.nih.gov/15614819/
- Li M, Falk BT, et al. Molecular mechanism of antimicrobial excipient-induced aggregation in parenteral formulations of peptide therapeutics. Molecular Pharmaceutics 2022;19(9):3267–3278: https://pubmed.ncbi.nlm.nih.gov/35917158/
- Centers for Disease Control and Prevention. Neonatal deaths associated with use of benzyl alcohol – United States. Morbidity and Mortality Weekly Report 1982;31(22):290–291: https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm
Everything above describes compendial standards, label wording and published stability data; none of it is a usage recommendation. Where a licensed medicine is involved, the approved label or summary of product characteristics is the controlling document, and questions about a specific preparation belong with a qualified physician or pharmacist.